0001062993-17-000505.txt : 20170203
0001062993-17-000505.hdr.sgml : 20170203
20170203180759
ACCESSION NUMBER: 0001062993-17-000505
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20161128
FILED AS OF DATE: 20170203
DATE AS OF CHANGE: 20170203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOSPECIFICS TECHNOLOGIES CORP
CENTRAL INDEX KEY: 0000875622
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 113054851
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 35 WILBUR ST
CITY: LYNBROOK
STATE: NY
ZIP: 11563
BUSINESS PHONE: 5165937000
MAIL ADDRESS:
STREET 1: 35 WILBUR STREET
CITY: LYNBROOK
STATE: NY
ZIP: 11563
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wegman Thomas
CENTRAL INDEX KEY: 0001355189
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34236
FILM NUMBER: 17573476
MAIL ADDRESS:
STREET 1: 1764 BRIAR PLACE
CITY: MERRICK
STATE: NY
ZIP: 11566
4/A
1
form4a.xml
AMENDED STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0306
4/A
2016-11-28
2016-11-29
0000875622
BIOSPECIFICS TECHNOLOGIES CORP
BSTC
0001355189
Wegman Thomas
C/O BIOSPECIFICS TECHNOLOGIES CORP.
35 WILBUR STREET
LYNBROOK
NY
11563
1
1
1
0
President
Common Stock, $.001 par value
2016-11-28
4
S
0
11055
48.0369
D
301494
D
Common Stock, $.001 par value
2016-11-29
4
S
0
8945
48.3161
D
292549
D
The selling price of $48.0369 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $47.50 to $49.40. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
The selling price of $48.3161 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $48.25 to $48.77. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
The purpose of this Form 4/A is solely to correct the amount of securities beneficially owned by the reporting person and does not represent any acquisition or disposition of shares by the reporting person.
/s/ Carl A. Valenstein, attorney-in-fact for Thomas Wegman
2017-02-03